A Phase 4 interventional study of Dexmedetomidine and Midazolam in Postoperative Pain, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-16.
Sponsored by Assiut University · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 136 studies testing dexmedetomidine in Pain, Postoperative — 35 open to participants now, 38 under way, 5 of them phase 3. Dexmedetomidine · Pain, Postoperative.
Among the 136 studies testing dexmedetomidine in Pain, Postoperative, this one is the 51st largest by planned enrollment, is one of 8 that started in 2023, is one of 49 in phase 4, reaches primary completion later than 3 of the 37 other live ones, and was the 80th registered.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
Browse Pain, Postoperative studies →35 of the 136 studies testing dexmedetomidine in Pain, Postoperative are open now, in 9 countries. Recruiting first, the newest first:
Minia University · Sites in Egypt
Ages 18–70
Vasiliki Samartzi · Sites in Greece
Ages 20–70 · Women only
Tanta University · Sites in Egypt
Ages 21–60
Beijing Tiantan Hospital · Sites in China
Ages 18–65
Rhode Island Hospital · Sites in United States
Ages 18–80
By country, each count listing its studies:
Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
136 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 24 · Phase 3 23 · Phase 4 49
First in 2008; this study’s year is marked. 8 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is above the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Median enrollment 85 across the 136 interventional studies. Of the 70 that completed or were terminated, 8 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 136 have an industry lead sponsor. The 10 most frequent:
Assiut University is the lead sponsor of 5,094 studies on the registry; 2,187 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
109 studies in Pain, Postoperative by Assiut University: 31 open now, 32 under way, 5 of them phase 3. Of 49 finished, 0 (0%) have results posted.
Among the 109 studies in Pain, Postoperative by Assiut University, this one is the 21st largest by planned enrollment of the 108 interventional ones that give a count, is one of 5 that started in 2023, is one of 10 in phase 4, reaches primary completion later than 2 of the 31 other live ones, and was the 78th registered.
Assiut University’s Pain, Postoperative studies by the year they started, since 2013.
15 of the studies testing dexmedetomidine in Pain, Postoperative that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07878156Phase 3Children's Cancer Hospital Egypt 57357Dexmedetomidine Use for Greater Occipital Nerve Block in Pediatric Posterior Fossa Tumor Surgery. | 2026-12-30 |
| NCT07434310Phase 3Dr. Naveed SiddiquiUse of Dexmedetomidine to Improve Pain Control and Recovery After Laparocopic-Assisted Bowel Surgery in Adults | 2027-07-01 |
| NCT07847047Phase 3Assiut UniversitySafety and Efficacy of Dexamethasone Versus Dexmedetomidine as Adjuvants in PENG Block in Hip Surgeries for Postoperative Pain Management | 2027-10 |
| NCT07846722Vasiliki SamartziEsmolol Versus Dexmedetomidine for Opioid-sparing in Laparoscopic Gynecological Surgery | 2026-12-01 |
| NCT07099222University of ArizonaEfficacy of Non-weight Based, Low Dose Dex-Dex Adjuncts in Prolonging Peripheral Nerve Blocks | 2026-12-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 136 studies testing dexmedetomidine in Pain, Postoperative, from their registry updates:
Among Assiut University’s 109 in Pain, Postoperative:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to compare the postoperative analgesic effect of intrathecal dexmedetomidine combined with bupivacaine and midazolam combined with bupivacaine in high tibial osteotomy.
With more than 80% of patients experiencing acute pain following surgical procedures, and half of them reporting inadequate pain therapy, the control and management of post-surgical pain remains one of the most challenging aims of modern anesthesia.
Adequate postoperative pain control is an important part of postoperative care treatment. World Health Organization, as well as International Association for the Study of Pain, have emphasized its significance for patients well-being, and determined pain relief to be a human right and the occurrence of pain as fifth vital sign.
Local anesthetic, bupivacaine, is the most common agent used for spinal anesthesia but has relatively short duration of action. Many adjuvants to local anesthetics have been used intrathecally to improve the quality of intraoperative analgesia and prolong it in the postoperative period.
Diverse classes of drugs such as opioids , epinephrine , neostigmine , magnesium , midazolam , ketamine , and clonidine have been added to intrathecal local anaesthetics in an attempt to prolong analgesia and reduce the incidence of adverse events.
Opioids are commonly added to local anaesthetics to produce spinal and epidural anesthesia. However, significant adverse effects such as, urinary retention, respiratory depression, hemodynamic instability, pruritus and occasionally severe nausea and vomiting, may limit their use .
α2-adrenergic agonists are new neuraxial adjuvants being studied to improve the quality of subarachnoid blockade regarding both sensory and motor blockades. There are many studies supporting their efficacy as adjuvants individually.
Dexmedetomidine, a highly specific, potent, and selective α2-adrenergic agonist, provides stable hemodynamic conditions and good quality of intraoperative and prolonged postoperative analgesia with minimal side effects.
Discovery of benzodiazepine receptors in spinal cord in 1977 triggered the use of intrathecal midazolam for prolongation of spinal anesthesia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
includes thirty patients who receive intrathecal 4 mL (20 mg) 0.5% hyperbaric bupivacaine and 1 mg midazolam (8 units of 5 mg/mL preservative-free midazolam loaded in a 40 unit insulin syringe).
Drug: Midazolam · Drug: Bupivacain
includes thirty patients who receive intrathecal 4 mL (20 mg) 0.5% hyperbaric bupivacaine and 5 mcg dexmedetomidine (2 units of 100 mcg/mL preservative-free dexmedetomidine loaded in a 40 unit insulin syringe).
Drug: Dexmedetomidine · Drug: Bupivacain
includes thirty patients who receive intrathecal 4 mL (20 mg) 0.5% hyperbaric bupivacaine and 0.5 mL of 0.9% saline .
Drug: Bupivacain
Under strict aseptic conditions, a lumbar puncture will be performed with selective technique in sitting position at L2-3 or L3-4 interspaces with midline approach using a 25-G Quincke's needle. After achieving the free flow of cerebrospinal fluid, the study drug will be injected into the subarachnoid space, immediately after injection the patient will be asked for supine position.
1 mg midazolam intrathecal administration
20 mg bupivacaine intrathecal administration
Time to first analgesic request
Time to first analgesic request calculated from the administration of local anesthetic
Time frame: 24 hours
analgesic consumption
Total analgesic consumption in the first 24 hour .
Time frame: 24 hours
Incidence of complications
Incidence of complications (bradycardia , hypotension ,nausea and vomiting).
Time frame: 24 hours
No study locations are listed for this record.
Start is estimated for Nov 2023; primary completion for Nov 2024, 12 months later.
Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 12 months is below that.
Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dexmedetomidine · Midazolam